NEW YORK (GenomeWeb) – Emerging biotechnology company Locus Biosciences announced today that it has closed a $5 million convertible note, and will use the funds to support the development of antimicrobial therapeutics based on CRISPR-Cas3 technology.

Financing for the round was led by Chinese Internet services provider Tencent Holdings and was joined by the North Carolina Biotechnology Center. Locus said the funding will help it advance development on several infectious disease products targeting antibiotic resistant infections and other microbiome-related diseases.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.